EZH2 inhibitor combination therapies
This invention relates to combination therapies comprising an EZH2 inhibitor and a chemotherapeutic agent, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses.
1. A method of treating small cell lung cancer (SCLC) in a subject comprising a first step of administering to the subject a combination therapy which comprises 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one, and a platinum based antineoplastic agent, and a second step of administering to the subject a monotherapy of 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one, wherein the second step does not include administering to the subject said platinum based antineoplastic agent.
2. The method of claim 1 , wherein the subject is a human.
3. The method of claim 1 , wherein the small cell lung cancer is classified as extensive stage disease.
4. The method of claim 1 , wherein the subject is treatment naive.
5. The method of claim 1 , wherein the platinum based anti-neoplastic agent is selected from the group consisting of cisplatin and carboplatin.
6. The method of claim 5 , wherein the platinum based anti-neoplastic agent is cisplatin.
7. The method of claim 5 , wherein the platinum based anti-neoplastic agent is carboplatin.
8. The method of claim 1 , wherein the second step of monotherapy is maintained for at least three weeks.